AGM
NWBO

Alpine Global Management’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

Alpine Global Management’s Portfolio NWBO Stock Details NWBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-110,187
Closed -$64K – 251
2016
Q2 		$64K Buy
+110,187
New +$118K 0.03% 154

Other funds holding NWBO

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CDH
Charles D. Hyman $1.79B AUM 17.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Alpine Global Management's NWBO Position: Q3 2016 in Review

Alpine Global Management sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q3 2016, closing a stake of 110,187 shares — an estimated $64K sold.

Alpine Global Management first reported a position in NWBO in Q2 2016 and held it in 1 quarter. The position peaked at $64K in Q2 2016. 54 funds tracked by Wall St. Rank hold NWBO as of Q3 2016.

  • Alpine Global Management reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q3 2016 after selling out during the quarter.
  • Alpine Global Management sold 110,187 Northwest Biotherapeutics, Inc. Common stock shares in Q3 2016, an estimated $64K.
  • Alpine Global Management first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q2 2016 and held it in 1 quarter.
  • Alpine Global Management's Northwest Biotherapeutics, Inc. Common stock position peaked at $64K in Q2 2016.
  • 54 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q3 2016.

Based on Alpine Global Management's 13F filing for Q3 2016, filed 15 Nov 2016.